Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies von Podhorna, Jana, Krahnke, Tillmann, Shear, Michael, Harrison, John E

Volltext

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 (RIPK1) inhibitor eclitasertib (SAR443122) in patients with severe COVID-19: a phase 1b, randomized,... von Clot, Pierre-Francois, Farenc, Christine, Suratt, Benjamin T, Krahnke, Tillmann, Tardat, Agnes, Florian, Peter, Pomponio, Robert, Patel, Naimish, Wiekowski, Maria, Lin, Yong, Terrier, Benjamin, Staudinger, Heribert

Volltext

Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic P... von CORTES, Jorge E, BACCARANI, Michele, MOIRAGHI, Beatriz, ROWE, Jacob M, TOTHOVA, Elena, DE SOUZA, Carmino, RUDOLTZ, Marc, YU, Richard, KRAHNKE, Tillmann, KANTARJIAN, Hagop M, RADICH, Jerald P, HUGHES, Timothy P, GUILHOT, François, DRUKER, Brian J, BRANFORD, Susan, KIM, Dong-Wook, PANE, Fabrizio, PASQUINI, Ricardo, GOLDBERG, Stuart L, KALAYCIO, Matt

Volltext

A Single-Dose Comparison of the Acute Effects between the New Somatostatin Analog SOM230 and Octreotide in Acromegalic Patients von van der Hoek, Joost, de Herder, Wouter W., Feelders, Richard A., van der Lely, Aart-Jan, Uitterlinden, Piet, Boerlin, Viktor, Bruns, Christian, Poon, Kwai W., Lewis, Ian, Weckbecker, Gisbert, Krahnke, Tillmann, Hofland, Leo J., Lamberts, Steven W.

Volltext

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study von Larson, Richard A., Druker, Brian J., Guilhot, Francois, O'Brien, Stephen G., Riviere, Gilles J., Krahnke, Tillmann, Gathmann, Insa, Wang, Yanfeng

Volltext

Immunomodulatory and clinical effects of receptor-interacting protein kinase 1 in patients with severe COVID-19: a phase 1b, randomized, double-blinded, placebo-controlled study von Clot, Pierre-Francois, Farenc, Christine, Suratt, Benjamin T, Krahnke, Tillmann, Tardat, Agnes, Florian, Peter, Pomponio, Robert, Patel, Naimish, Wiekowski, Maria, Lin, Yong, Terrier, Benjamin, Staudinger, Heribert

Volltext

Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of inte... von Hochhaus, Andreas, Druker, Brian, Sawyers, Charles, Guilhot, Francois, Schiffer, Charles A., Cortes, Jorge, Niederwieser, Dietger W., Gambacorti-Passerini, Carlo, Stone, Richard M., Goldman, John, Fischer, Thomas, O'Brien, Stephen G., Reiffers, Jose J., Mone, Manisha, Krahnke, Tillmann, Talpaz, Moshe, Kantarjian, Hagop M.

Volltext

A Longitudinal Item Response Theory Model to Characterize Cognition Over Time in Elderly Subjects von Vandemeulebroecke, Marc, Bornkamp, Björn, Krahnke, Tillmann, Mielke, Johanna, Monsch, Andreas, Quarg, Peter

Volltext

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase von Kantarjian, Hagop M., Larson, Richard A., Guilhot, Francois, O'Brien, Stephen G., Mone, Manisha, Rudoltz, Marc, Krahnke, Tillmann, Cortes, Jorge, Druker, Brian J.

Volltext

Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3... von Roy, Lydia, Guilhot, Joëlle, Krahnke, Tillmann, Guerci-Bresler, Agnès, Druker, Brian J., Larson, Richard A., O'Brien, Steve, So, Charlene, Massimini, Giorgio, Guilhot, François

Volltext

P1‐329: ITEM RESPONSE THEORY (CERAD, CVLT) von Monsch, Andreas U., Mielke, Johanna, Vandemeulebroecke, Marc, Krahnke, Tillmann, Quarg, Peter

Volltext

ITEM RESPONSE THEORY (CERAD, CVLT) von Monsch, Andreas U, Mielke, Johanna, Vandemeulebroecke, Marc, Krahnke, Tillmann, Quarg, Peter

Volltext

P4‐185: UP‐TITRATION TO HIGH‐DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H... von Molinuevo, José L., Cummings, Jeffrey, Frolich, Lutz, Galvin, James E., Krahnke, Tillmann, Strohmaier, Christine

Volltext

UP-TITRATION TO HIGH-DOSE 13.3 MG/24 H RIVASTIGMINE TRANSDERMAL PATCH MAY PROVIDE GREATER BENEFIT TO ALZHEIMER'S DISEASE PATIENTS COMPARED TO CONCOMITANT USE OF 9.5 MG/24 H PATCH A... von Molinuevo, José L, Cummings, Jeffrey, Frolich, Lutz, Galvin, James E, Krahnke, Tillmann, Strohmaier, Christine

Volltext

Incidence and predictors of response to the 13.3 (15 cm2 ) and 9.5 mg/24h (10 cm2 ) rivastigmine patch in the OPtimising Transdermal Exelon In Mild-to-moderate Alzheimer's disease... von Molinuevo, Jose Luis, Grossberg, George, Frölich, Lutz, Galvin, James, Krahnke, Tillmann, Strohmaier, Christine

Volltext

P3–275: Incidence and predictors of response to the 13.3 (15 cm2) and 9.5 mg/24h (10 cm2) rivastigmine patch in the OPtimising Transdermal Exelon In Mild‐to‐moderate Alzheimer's di... von Molinuevo, Jose Luis, Grossberg, George, Frölich, Lutz, Galvin, James, Krahnke, Tillmann, Strohmaier, Christine

Volltext

P3–278: The rivastigmine high‐dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPt... von Cummings, Jeffrey, Bellelli, Giuseppe, Black, Sandra, Bakchine, Serge, Krahnke, Tillmann, Strohmaier, Christine

Volltext

The rivastigmine high-dose, 13 mg/24h (15cm2), transdermal patch provides daily living benefits to people with severe Alzheimer's disease: Retrospective analyses of the OPtimising... von Cummings, Jeffrey, Bellelli, Giuseppe, Black, Sandra, Bakchine, Serge, Krahnke, Tillmann, Strohmaier, Christine

Volltext

Efficacy of Higher Dose 13.3 mg/24 h Rivastigmine Patch on Instrumental Activities of Daily Living in Patients with Mild-to-Moderate Alzheimer's Disease von Grossberg, George, Cummings, Jeffrey, Frölich, Lutz, Bellelli, Giuseppe, Molinuevo, José L., Krahnke, Tillmann, Strohmaier, Christine

Volltext

Responder analysis of a randomized comparison of the 13.3 mg/24 h and 9.5 mg/24 h rivastigmine patch von Molinuevo, José L, Frölich, Lutz, Grossberg, George T, Galvin, James E, Cummings, Jeffrey L, Krahnke, Tillmann, Strohmaier, Christine

Volltext